Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said a single intradermal electroporation boost of its SynCon avian influenza vaccine generated hemagglutination inhibition (HAI) titers against six different unmatched strains of H5N1, and it generated a fourfold or greater rise in HAI titers in 50 percent of boosted subjects in a Phase I study.